Medium materiality6/10
TransMedics price target lowered to $94 from $95 at Canaccord
Why it may matterVerify against the original reporting
Upside remains; small downgrade but still above price.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
TransMedics price target lowered to $94 from $95 at Canaccord.
- Canaccord trims TMDX target to $94 from $95.
Key facts
- 01
Target: $94
- 02
Posted price: $78.17
- 03
Analyst firm: Canaccord Genuity
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.